Survival was extended by 91 % in dogs
receiving pimobendan compared with those receiving benazepril hydrochloride.2 *
The 360 canine patients enrolled in the trial randomly
received pimobendan or a placebo, with 180 dogs in each group.
Not exact matches
The EPIC Study showed that administration of
pimobendan resulted in a 15 ‑ month delay in time to primary endpoint compared with dogs
receiving placebo.
The EPIC Study showed that administration of
pimobendan resulted in a 15 ‑ month delay in onset of clinical signs of CHF, cardiac ‑ related death, or euthanasia compared with dogs
receiving placebo.
Sixty - four dogs
received a standard dose of
pimobendan (0.20 — 0.48 mg / kg every 12 hr (q12hr)-RRB-, 49 dogs
received a low dose of
pimobendan (0.05 — 0.19 mg / kg q12hr) and 84 dogs
received conventional therapy alone.
The EPIC study (Evaluation of
Pimobendan In Cardiomegaly) found pimobendan extended the asymptomatic period by an average of 15 months, while dogs that received the drug also lived significantly longer than those receiving
Pimobendan In Cardiomegaly) found
pimobendan extended the asymptomatic period by an average of 15 months, while dogs that received the drug also lived significantly longer than those receiving
pimobendan extended the asymptomatic period by an average of 15 months, while dogs that
received the drug also lived significantly longer than those
receiving a placebo.